


GSK delivers strong Q3 performance and upgrades 2025 guidance

“GSK’s momentum continues with another quarter of strong performance, supporting upgraded guidance for 2025, and positioning us well for 2026 and achieving our longer-term growth outlooks. Sales grew in all areas, with particularly strong performances in Specialty Medicines driven by double-digit growth in Respiratory Inflammation & Immunology, Oncology and HIV. We have also continued to make very good progress in R&D with four FDA product approvals so far this year, including for *Blenrep* in the US last week, and the start of pivotal trials and targeted business development to advance 15 scale pipeline opportunities, all launching before 2031.”

Emma Walmsley
Chief Executive Officer, GSK



Specialty Medicines

£3.4bn +16%

Respiratory, Immunology and Inflammation +15%
Oncology +39%
HIV +12%

Vaccines

£2.7bn +2%

General Medicines

£2.5bn +4%

Core operating
profit

£3.0bn
+11%

Total EPS

49.9p
>100%

Core EPS

55.0p
+14%

Dividend

16p

4

major new
product approvals
so far this year

15

scale
opportunities
expected to
launch 2025-2031

62

medicines
and vaccines
in pipeline

16

medicines
and vaccines
in phase III
development

Journalists/media see press release on www.gsk.com for full details on Q3 2025.

Please read the cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures on pages 18, 23-24, and 50-53 of the press release.

Product group sales may not add to total sales due to rounding.

References to growth are at constant exchange rates (CER) unless stated otherwise.

Ahead Together